CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Lenvima for Hepatocellular Carcinoma – Details

Project Number PC0175-000
Brand Name Lenvima
Generic Name Lenvatinib
Strength 4 mg & 12 mg
Tumour Type Gastrointestinal
Indication Hepatocellular Carcinoma
Funding Request For the first-line treatment of adult patients with unresectable Hepatocellular Carcinoma (HCC)
Review Status Complete
Pre Noc Submission No
NOC Date December 19, 2018
Manufacturer Eisai Limited
Sponsor Eisai Limited
Submission Date February 8, 2019
Submission Deemed Complete February 25, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ February 25, 2019
Check-point meeting April 12, 2019
pERC Meeting June 20, 2019
Initial Recommendation Issued July 5, 2019
Feedback Deadline ‡ July 19, 2019
Final Recommendation Issued July 24, 2019
Notification to Implement Issued August 9, 2019
Therapeutic Area Hepatocellular Carcinoma (HCC)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.